Scarica l'app Stockscreener
5.155
4.71%
-0.255
Dopo l'orario di chiusura:
5.30
0.145
+2.81%
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Great Point Partners LLC Bolsters Position in Outlook Therapeuti - GuruFocus.com
Learn to Evaluate (OTLK) using the Charts - Stock Traders Daily
Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks
Velan Capital Investment Management LP Increases Stake in Outloo - GuruFocus.com
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Aterian Investment Partners acquires Outlook Group to support growth - Packaging Gateway
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewswire
Outlook Therapeutics CEO to Present at Guggenheim Healthcare Conference After EU Win | OTLK Stock News - StockTitan
Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
(OTLK) Trading Signals - Stock Traders Daily
The United States Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook, 2030 - Grand View Research
Outlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG Research - MarketBeat
Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment - Marketscreener.com
How the (OTLK) price action is used to our Advantage - Stock Traders Daily
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Severe Acute Respiratory Syndrome (SARS) Therapeutics Market 2023 Outlook By Product, Trends and Forecast To (2024-2034) – IndiaPolitics.com - IndiaPolitics.com
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ForexTV.com
ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important - EIN News
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Outlook Therapeutics Awaits Wet AMD Trial Results Of ONS-5010 - RTTNews
OTLK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionOTLK - AsiaOne
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(OTLK) On The My Stocks Page - Stock Traders Daily
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts - Benzinga
Outlook Therapeutics CFO buys $28.4k in company stock - Investing.com India
Insider Buying: CFO Lawrence Kenyon Acquires Shares of Outlook T - GuruFocus.com
Outlook Therapeutics CFO buys $28.4k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics' SWOT analysis: navacaprant's potential lifts stock outlook - Investing.com
Great Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
(OTLK) Investment Analysis - Stock Traders Daily
Great Point Partners LLC Grows Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World
Checking in on Outlook Therapeutics Inc (OTLK) after recent insiders movement - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing Outlook Therapeutics Inc (OTLK)’s Performance - The Dwinnex
A year in review: Outlook Therapeutics Inc (OTLK)’s performance in the last year - US Post News
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - ForexTV.com
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - GlobeNewswire
OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Outlook Therapeutics Inc (OTLK) Becoming More Attractive for Investors - Knox Daily
UK Asthma Therapeutics Market Size & Outlook, 2023-2030 - Grand View Research
Private equity firms are Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners and were rewarded after market cap rose by US$30m last week - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Outlook Therapeutics Inc [OTLK] Shares Jump Approximately 62.65% Over the Year - Knox Daily
Iovance Therapeutics: Historic Product, Tough Commercial Outlook - Seeking Alpha
Outlook Therapeutics completes NORSE EIGHT enrollment - Investing.com
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics (NASDAQ:OTLK) Price Target Lowered to $33.00 at Ascendiant Capital Markets - Defense World
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):